Anne Novak
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2026
Year:
2026
Year:
2026
Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling (GEP) assay, which was developed and trained using 265 formalin-fixed, paraffin-embedded tissue samples on a reliable platform to predict, at the time of diagnosis, whether a patient will experience an event within 24 months. The modeling also confirmed and relied upon previously reported synergy between immune response (IR) gene expression signatures IR1 and IR2. Once locked, the 5-factor logistic regression FL24Cx model was independently validated in a retrospectively assessed cohort of 232 patients from 2 immunochemotherapy-treated arms of SWOG Cancer Research Network S0016 phase 3 clinical trial, in which it assigned 169 patients to the low-risk group with 29 events before 24 months (17.2%) and 63 patients to the high-risk group with 24 events before 24 months (38.1%). The relative risk of an event within 24 months after registration among patients who were classified into the high-risk group relative to patients who were classified into the low-risk group was 2.2 (95% confidence interval, 1.41 to 3.51). An up-front GEP biomarker, such as the FL24Cx, rigorously validated in a clinical laboratory and with a clinically relevant turnaround time, could identify and steer enrollment of patients at high risk for early events in clinical trials, thus enabling timely interpretation of such trials and increasing the pace of innovation.
Year:
2025
Supplementary Figure 7 A. Heat map of Spearman's correlation coefficients among paired metabolites in the bone marrow (BM) supernatant and peripheral blood (PB) serum of 12 patients with WM. Positive correlations are shown in red, whereas negative correlations are indicated in blue. B. Heat map showing different expression of 44 metabolites in the BM supernatant among the three molecular clusters. The left bar shows correlation coefficients between BM and PB metabolites. Gray squares indicate non significance.
Year:
2025
Supplementary Figure 5 A. Heat map of Spearman's correlation coefficients among paired proteins in the bone marrow (BM) supernatant and peripheral blood (PB) serum of 16 patients with WM (n=11) and IgM MGUS (n=5). Positive correlations are shown in red, whereas negative correlations are indicated in blue. B. Heat maps showing expression of (i) 12 proteins significantly different between C1 vs C2 plus C3, and (i) 74 proteins significantly different between C2 vs C1 plus C3 in the PB serum. The left bar shows correlation coefficients between BM and PB proteins. Gray squares indicate non significance.
Year:
2025
Supplementary Figure 6 Boxplots showing the expression of indicated metabolites in C1 (red), C2 (blue) and C3d (green). Differences between groups were calculated with the Mann-Whitney U test. ns, non-significant.
Year:
2025
Supplementary Figure 9 SPADE maps of CD4+ CTLA-4+ T cells from concatenated files (C1, n=7; C2, n=4). The dots in red and blue indicate high and low expression, respectively. The dot size is representative of cell events, with the big size containing more cell events.
Year:
2025
Twenty percent of patients with follicular lymphoma relapse early with poor outcomes; however, the molecular mechanisms underlying this aggressive behavior are unknown. Using a multiomic approach, we show that patients with follicular lymphoma with elevated IRF4 expression (IRF4 hi ) have increased transformation risk, dysregulated immune signaling, and a suppressive tumor microenvironment. Loss- and gain-of-function experiments in IRF4 hi lymphoma cells, along with chromatin profiling, demonstrate that IRF4 impairs their interaction with T cells by repressing antigen presentation and co-receptor gene modules while promoting the expression of cytokines that antagonize T-follicular helper cell and regulatory T-cell functions. Additionally, IRF4 rewires tumor metabolism and restricts glucose availability to immune cells. Silencing of IRF4 inhibits tumor cell growth and restores immune surveillance mechanisms, thus representing a promising target for therapy. Our data suggest that IRF4 hi lymphoma cells co-opt a developmental mechanism used to exit the germinal center response in promoting a more aggressive cancer via engagement of multiple immune-evasive mechanisms. Significance: We show that IRF4 controls immune and metabolic signaling with functional effects on the cross-talk between B and T cells, resulting in a suppressive immune microenvironment when IRF4 is overexpressed in lymphoma. This underscores the importance of IRF4 as a pivotal therapeutic target to restore antitumor immunosurveillance for IRF4-associated lymphomas.
Year:
2025
Up to 40% of diffuse large B-cell lymphoma (DLBCL) patients do not experience a durable response to frontline immunochemotherapy, and prospective identification of high-risk cases that may benefit from personalized therapeutic management remains an unmet need. Molecular phenotyping techniques have established a landscape of genomic variants in diagnostic DLBCL; however, these have not yet been applied in large-scale studies of relapsed/refractory DLBCL, resulting in incomplete characterization of mechanisms driving tumor progression and treatment resistance. Here, we performed an integrated multiomic analysis on 228 relapsed/refractory DLBCL samples, including 24 with serial biopsies. Refined cell-of-origin subtyping identified patients harboring GCB and DZsig+ relapsed/refractory tumors in cases with primary refractory disease with remarkably poor outcomes, and comparative analysis of genomic features between relapsed and diagnostic samples identified subtype-specific mechanisms of therapeutic resistance driven by frequent alteration to MYC , BCL2 , BCL6 , and TP53 among additional strong lymphoma driver genes. Tumor evolution dynamics suggest innate mechanisms of chemoresistance are present in many DLBCL tumors at diagnosis, and that relapsed/refractory tumors are primarily comprised of a homogenous clonal expansion with reduced tumor microenvironment activity. Adaptation of personalized therapeutic strategies targeting DLBCL subtype-specific resistance mechanisms should be considered to benefit these high-risk populations.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (14)
Matthew Maurer
Professor of Biostatistics
Mayo Clinic Rochester
Esteban Braggio
Assistant Professor
Mayo Clinic
James Cerhan
Professor of Epidemiology
Mayo Clinic Rochester
Laura Pasqualucci
Professor of Pathology and Cell Biology
Columbia University
Harinder Singh
Professor and Director
University of Pittsburgh
George Wright
National Institutes of Health
Morie Gertz
Mayo Clinic
Junwen Wang
Professor
The University of Hong Kong
Karen Adelman
Professor
Harvard Medical School
Susan Slager
Professor
Mayo Clinic Minnesota
Zhiquan Wang
Assistant Professor
Mayo Clinic
Lisa Rimsza
Professor and Chair
Mayo Clinic Arizona
Mark J. Shlomchik
Distinguished Professor
University of Pittsburgh
Jonas Paludo
Assistant Professor of Medicine and Oncology
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.